|
| Key figures: Diagnostics Division |
|
|
In millions of CHF
|
% change in CHF
|
% change in local currencies
|
As % of sales
|
|
Sales
|
4,902
|
3
|
7
|
100
|
|
— Professional Diagnostics
|
2,238
|
4
|
9
|
46
|
|
— Diabetes Care
|
1,438
|
–3
|
3
|
29
|
|
— Molecular Diagnostics
|
594
|
5
|
6
|
12
|
|
— Applied Science
|
403
|
8
|
8
|
8
|
|
— Tissue Diagnostics
|
229
|
40
|
33
|
5
|
|
Operating profit
|
644
|
11
|
28
|
13.1
|
|
Operating free cash flow
|
507
|
102
|
131
|
10.3
|
Roche’s Diagnostics Division performed strongly in the first half of 2009. Divisional sales again grew significantly faster than the market, with strong uptake of new products contributing to market share gains in key segments such as immunoassays. All five business areas launched major new products. The operating profit and operating margin increased, helped by strong sales growth and ongoing improvements in operational efficiency.
Europe/Middle East/Africa (+7%), Japan (–3%), Asia—Pacific (+22%), Latin America (+16%), North America Other (–11%)
In the first half of 2009 the Diagnostics Division recorded sales of 4.9 billion Swiss francs, an increase of 7% in local currencies (3% in Swiss francs; –4% in US dollars) over the first six months of 2008.1 This was more than twice the estimated growth of the invitro diagnostics market (3%). Second-quarter sales totalled 2.5 billion Swiss francs, up 7% from the year earlier period. All five business areas increased their half-year sales, led by Professional Diagnostics and Tissue Diagnostics. Regionally, the strongest growth occurred in Asia—Pacific and Latin America, with all business areas contributing. Tissue Diagnostics was the primary sales driver in North America. In Japan Professional Diagnostics and Tissue Diagnostics achieved good growth, but overall sales were down slightly. In April Roche acquired innovatis AG, a leader in automated cell analysis solutions; integration activities are already well underway. Integration of Swisslab GmbH, a leading European supplier of laboratory information systems, acquired in December 2008, has been completed. The acquisitions expand and strengthen the portfolios of the Applied Science and Professional Diagnostics businesses, respectively.
Roche’s top-selling diagnostics
|
|
Product lines
|
Market segment
|
Business area
|
Sales in millions of CHF
|
% change in local currencies
|
|
Accu-Chek meters
|
Blood glucose monitoring
|
Diabetes Care
|
1,333
|
3
|
|
cobas e modules,
Modular Analytics, Elecsys
|
Immunoassays
|
Professional Diagnostics
|
789
|
18
|
|
cobas c modules,
Modular Analytics,
Cobas Integra
|
Clinical chemistry
|
Professional Diagnostics
|
638
|
3
|
|
cobas AmpliPrep/
cobas TaqMan
|
Virology
|
Molecular Diagnostics
|
283
|
4
|
|
cobas AmpliScreen,
cobas TaqScreen
|
Blood screening
|
Molecular Diagnostics
|
158
|
10
|
|
CoaguChek
|
Coagulation monitoring
|
Professional Diagnostics
|
140
|
24
|
|
Immunohistochemistry
reagents
|
Advanced tissue staining
|
Tissue Diagnostics
|
138
|
39
|
|
MagNA Pure/LightCycler
|
Gene expression research
|
Applied Science
|
103
|
11
|
Major product launches in the first half of 2009
|
|
Business area
|
Product
|
Quarter
|
|
Professional Diagnostics
|
High-sensitivity Elecsys Troponin T immunoassay for the diagnosis of heart attack and cardiac risk stratification (EU)
|
Q1
|
|
Elecsys immunoassays for PlGF (placenta growth factor) and sFlt1 (soluble fms-like tyrosine kinase 1) for the diagnosis of preeclampsia (EU)
|
Q1
|
|
Elecsys IL-6 (interleukin-6) immunoassay to aid the management of critically ill patients (EU)
|
Q1
|
|
Elecsys Troponin I Assay: test for cardiac-specific troponin I levels to predict mortality risk in patients with acute coronary syndrome (EU)
|
Q2
|
|
Sysmex XT-4000i: new-generation automated hematology analyser with test capabilities for whole blood and other body fluids (contractual territory in EMEA)
|
Q2
|
|
Diabetes Care
|
Accu-Chek Mobile: integrated lancing and blood glucose monitoring device employing a unique ‘no strip’ technology that replaces test strips with a continuous tape of 50 tests (EU)
|
Q1
|
|
Accu-Chek Aviva Nano and Accu-Chek Performa Nano: sleeker versions of the Accu-Chek Aviva and Accu-Chek Performa meters offering an enhanced feature set (EU)
|
Q1
|
|
Accu-Chek Active: new version of an existing meter, featuring an extended
test memory and a number of fail-safe capabilities (EU)
|
Q1
|
|
Accu-Chek Combo: diabetes management system combining an insulin pump with a glucose meter that also functions as a pump remote control (EU)
|
Q1
|
|
Molecular Diagnostics
|
MRSA Advanced Test: automated real-time test for methicillin-resistant Staphylococcus aureus. The test can identify MRSA carriers in under two hours (EU)
|
Q2
|
|
Applied Science
|
xCELLigence RTCA DP (dual plate) system: highly flexible medium-throughput system for real-time non-invasive cell analysis (worldwide)
|
Q2
|
|
LightCycler 1536 system for high-throughput quantitative PCR analysis
(worldwide)
|
Q2
|
|
NimbleGen MS 200: fully automated high-resolution microarray scanner for use with all NimbleGen DNA microarrays (worldwide)
|
Q2
|
|
Tissue Diagnostics
|
INFORM EGFR DNA Probe: detects extra copies of the epidermal growth factor receptor (EGFR) gene, an abnormality associated with non-small cell lung cancer (EMEA, APAC)
|
Q1
|
|
Intended use of CONFIRM anti HER2/neu Primary Antibody and INFORM HER2 DNA Probe expanded to include analytical claims regarding performance with gastric as well as breast tissue samples (EMEA, APAC)
|
Q2
|
|
Pharmaceuticals & Health Care 
